ABEONA THERAPEUTICS INC.
ABEO evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ABEO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ABEO
Abeona Therapeutics Inc. is a biopharmaceutical company focused on developing cell and gene therapies for rare diseases, with a lead commercial product ZEVASKYN® and a pipeline candidate ABO-701 in preclinical development.
Key risk: Funding and liquidity risk
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 3 clinical trials for ABEONA THERAPEUTICS INC..
Abeona Therapeutics Inc. is a biopharmaceutical company focused on developing cell and gene therapies for rare diseases, with a lead commercial product ZEVASKYN® and a pipeline candidate ABO-701 in preclinical development.
- Cash and equivalents of $56.2M as of 2026-06-30 [sec].
- Total revenue of $11.4M and net loss of -$20.2M for the six months ended 2026-06-30 [sec].
- Shareholders' equity of $163.6M and total debt of $28.3M as of 2026-06-30 [sec].
- Lead product ZEVASKYN® is commercialized; pipeline candidate ABO-701 is in preclinical development with an IND submission planned [sec filed 2026-06-04].
- Company has an ATM agreement with up to $51.5M in remaining shares available as of 2026-06-30 [sec_mda as of 2026-08-13].
What works
- Abeona has a commercial product, ZEVASKYN®, generating revenue and providing a foundation for future growth [sec_mda as of 2026-08-13].
- The company maintains a strong cash position of $56.2M as of 2026-06-30, with an ATM facility providing additional financing flexibility [sec].
- Abeona's pipeline includes ABO-701, a gene therapy candidate targeting a rare disease, with a planned IND submission [sec filed 2026-06-04].
What to weigh
- Abeona has incurred significant operating losses and negative cash flows since inception, excluding the gain on sale of a priority review voucher [sec_mda as of 2026-08-13].
- The company may need to secure additional funding to complete all planned R&D and commercialization activities, and failure to do so could delay or terminate programs [sec_mda as of 2026-08-13].
- ABO-701 is still in preclinical development, with regulatory and clinical risks that could affect its timeline and success [sec filed 2026-06-04].
From the filings
Quoted directly from source documents.
Remaining shares available under ATM agreement as of 2026-06-30
“we have remaining shares of our common stock for an aggregate sales price of up to $51.5 million”
SEC MD&A · August 13, 2026
ABO-701 IND submission timing
“the Company's expectations with respect to the timing of the IND submission for ABO-701”
SEC filings · June 4, 2026
Risks & what to watch (3)›
Key risks
- Funding and liquidity risk — Abeona may need additional financing to complete R&D; failure could delay or terminate programs [sec_mda as of 2026-08-13].
- Preclinical development risk — ABO-701 is in preclinical stage; regulatory and clinical risks could delay or prevent approval [sec filed 2026-06-04].
- Commercialization risk — ZEVASKYN® commercialization success is uncertain and depends on market adoption and reimbursement [sec_mda as of 2026-08-13].
What to watch
- Progress of ABO-701 IND submission and regulatory interactions [sec filed 2026-06-04].
- Cash burn rate and potential need for additional financing [sec_mda as of 2026-08-13].
- ZEVASKYN® revenue trends and market adoption [sec_mda as of 2026-08-13].
Sources: SEC filings · SEC MD&A · Generated August 20, 2026 · How we verify sources →
Run ABEONA THERAPEUTICS INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ABEONA THERAPEUTICS INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
25.3 months
D/E 0.40 · 0% dilution
Lead: Approved
4 candidates
No upcoming catalysts tracked
0 buys · 21 sells (180d)
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
104
Total value held
$135.8M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 4,329,702 | $19.4M |
| blackrock, inc. | 3,195,530 | $14.3M |
| suvretta capital management, llc | 2,676,000 | $12.0M |
| kennedy capital management llc | 1,263,511 | $5.7M |
| geode capital management, llc | 1,209,797 | $5.4M |
| goldman sachs group inc | 1,130,619 | $5.1M |
| susquehanna international group, llp | 1,108,670 | $5.0M |
| state street corp | 957,328 | $4.3M |
| nan fung trinity (hk) ltd | 956,770 | $4.3M |
| stonepine capital management, llc | 846,587 | $3.8M |
Showing top 10 of 104 institutional holders of ABEONA THERAPEUTICS INC.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 31.1%
- Days to cover
- 16.9
- Shares short
- 16,486,060
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ABEO short interestGovernance
Frequently asked questions
What is the AI investment thesis for ABEONA THERAPEUTICS INC.?
Abeona Therapeutics Inc. is a biopharmaceutical company focused on developing cell and gene therapies for rare diseases, with a lead commercial product ZEVASKYN® and a pipeline candidate ABO-701 in preclinical development.
What is ABEONA THERAPEUTICS INC.'s lead drug candidate?
ABEONA THERAPEUTICS INC.'s most advanced tracked candidate is aav204 (Preclinical) for Ophthalmology indications.
Who is the CEO of ABEONA THERAPEUTICS INC.?
Dr. Vishwas Seshadri M.B.A., Ph.D. is the chief executive officer of ABEONA THERAPEUTICS INC. (ABEO).
Where is ABEONA THERAPEUTICS INC. headquartered?
ABEONA THERAPEUTICS INC. (ABEO) is headquartered in Cleveland, OH, United States.
What therapeutic areas does ABEONA THERAPEUTICS INC. focus on?
ABEONA THERAPEUTICS INC. develops therapies across Ophthalmology, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.